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Abstract
Background: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be
described as a member of the family of small round blue cell tumors. The molecular diagnostic marker is the t(11;
22)(p13;q12) translocation, which creates an aberrant transcription factor, EWS-WT1, that underlies the oncogenesis
of DSRCT. Current treatments are not very effective so new active drugs are needed. Trabectedin, now used as a
single agent for the treatment of soft tissue sarcoma, was reported to be active in some pre-treated DSRCT
patients. Using JN-DSRCT-1, a cell line derived from DSRCT expressing the EWS-WT1 fusion protein, we investigated
the ability of trabectedin to modify the function of the chimeric protein, as in other sarcomas expressing fusion
proteins. After detailed characterization of the EWS-WT1 transcripts structure, we investigated the mode of action of
trabectedin, looking at the expression and function of the oncogenic chimera.
Methods: We characterized JN-DSRCT-1 cells using cellular approaches (FISH, Clonogenicity assay) and molecular
approaches (Sanger sequencing, ChIP, GEP).
Results: JN-DSRCT-1 cells were sensitive to trabectedin at nanomolar concentrations. The cell line expresses
different variants of EWS-WT1, some already identified in patients. EWS-WT1 mRNA expression was affected by
trabectedin and chimeric protein binding on its target gene promoters was reduced. Expression profiling indicated
that trabectedin affects the expression of genes involved in cell proliferation and apoptosis.
Conclusions: The JN-DSRCT-1 cell line, in vitro, is sensitive to trabectedin: after drug exposure, EWS-WT1 chimera
expression decreases as well as binding on its target promoters. Probably the heterogeneity of chimera transcripts
is an obstacle to precisely defining the molecular mode of action of drugs, calling for further cellular models of
DSRCT, possibly growing in vivo too, to mimic the biological complexity of this disease.
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Background
Desmoplastic small round cell tumor (DSRCT) was first
described in 1989 by Gerald and Rosai [1] as a rare and
highly aggressive disease that usually occurs in males
during adolescence and early adulthood, with an estimated
annual incidence rate of 0.1 cases/per 1 million. Only a
few hundred cases have been reported worldwide. DSRCT
can be described as a member of the family of small round
blue cell tumors. All cases of DSRCT harbor the
t(11;22)(p13;q12) translocation, leading to fusion of the N-
terminal domain of Ewing’s sarcoma gene (EWS) to the C-
terminal DNA binding domain of Wilms tumor suppres-
sor gene (WT1). This unique chromosomal translocation
provides the definitive molecular diagnostic marker of
DSRCT and creates an aberrant transcription factor,
EWS-WT1, which underlies the oncogenesis [2, 3].
The extreme rarity of the disease and the lack of pros-
pective studies mean there is no consensus on the best
treatment [4]. The three main treatment modalities are
surgical resection (though complete resection is rarely pos-
sible), combination chemotherapy (response to conventional
doxorubicin-based therapy is very poor), and local radiother-
apy. In any case, current treatments for DSRCTs are not
curative and do not give long-term survival benefits [2].
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Despite aggressive therapy, 3-year overall survival is esti-
mated at 44% and the 5-year survival remains around 15%.
Two case reports, one by A.M. Frezza [4] and another
by A.L. Gonzalez [5], support trabectedin, which was ac-
tive and safe in pre-treated DSRCT patients, all refractory
to several lines of chemotherapy, and who remained stable
after trabectedin treatment.
Trabectedin (ET-743, Yondelis®) is a natural product
originally derived from Ecteinascidia turbinata, and currently
produced semi-synthetically. It has been previously reported
that it interacts with the minor groove of DNA through rings
A and B, and with several transcription factors, DNA binding
proteins and DNA repair molecules presumably through ring
C, which protrudes out of the DNA, inducing cell cycle per-
turbations that finally cause the cancer cell death (Fig. 1c) [6].
It is now used as a single agent for the treatment of soft
tissue sarcoma after failure of doxorubicin or ifosfamide, or
for patients that are unsuited for these molecules. It is also
used in combination with pegylated liposomal doxorubicin
for patients with relapsed, platinum-sensitive ovarian cancer.
Myxoid liposarcoma, characterized by the expression of the
oncogenic transcript FUS-CHOP, was extremely sensitive to
trabectedin [6, 7]. Preclinical studies indicated that this sensi-
tivity may be associated with trabectedin’s ability to block the
activity of FUS-CHOP chimera, allowing the tumor to differ-
entiate into benign lipoblasts. Displacement of the FUS-
CHOP chimera from the promoters of its target genes, block-
ing its transactivating function, was confirmed in tumor tis-
sues from biopsies of patients with myxoid liposarcomas
(MLS) treated with the drug [8]. Thus this event reactivates
adipocytic differentiation.
Starting from this assumption, we examined whether
DSRCT cells, characterized by the EWS-WT1 chimera ex-
pression, are sensitive to trabectedin, as in MLS. Prelimin-
ary results already indicate that the drug can be safely used
in heavily pretreated DSRCT patients, achieving worthwhile
control of symptoms, albeit temporary, with radiological
stabilization and regression of disease [4].
JN-DSRCT-1 is an established cell line derived from a
primary DSRCT specimen that naturally expresses EWS-
WT1 chimera [9]; this human cell line was obtained from
the pleural effusion of a 7-year-old boy with pulmonary
Fig. 1 JN-DSRCT-1 cell line resembles DSRCT disease characteristics. a 10X image of JN-DSRCT-1 cells. b EWS-WT1 fusion transcripts were detected in JN-
DSRCT-1 cells by FISH. Chromosome preparation from JN-DSRCT-1 cells hybridized with WT1 break-apart BAC probes: Spectrum Orange labeled RP1- 259 N9
(centromeric WT1 5’ end) and Spectrum Green labeled RP11-299P16 (telomeric WT1 3’ end). A fusion signal (corresponding to a non-translocated WT1 allele)
with two green signals (derivative chromosome 22) and an orange signal (derivative chromosome 11) are present in the metaphase andin the interphase
nucleus. The FISH pattern is coherent with EWS break-apart (not shown). c Trabectedin chemical structure and Clonogenic assay on JN-DSRCT-1 cells. The IC50
was calculated by PRISM GraphPad. d Cell cycle analysis after 1 h of treatment with trabectedin; the data were analyzed 24, 48 and 72 h after drug wash-out
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metastasis from a typical intra-abdominal DSRCT. Cells
were small round or spindle-shaped with oval nuclei and
have been maintained continuously in vitro for over 190
passages during more than 40 months. Histologic features
of the heterotransplanted tumors in the severe combined
immunodeficiency mouse were essentially the same as
those of the original DSRCT, with nests or clusters of
small round cells embedded in an abundant desmoplastic
stroma. JN-DSRCT-1 cells exhibited pathognomonic
t(11;22)(p13;q12) translocation by cytogenetic analysis.
RT-PCR and sequencing analysis showed a chimeric tran-
scriptional message of the Ewing’s sarcoma gene exon 10
fused to the Wilms’ tumor gene exon 8. Alternative spli-
cing in exon 9 of WT1 and EWS-WT1 generates an inser-
tion of three aminoacids -lysine, threonine and serine
(KTS)- between zinc fingers 3 and 4, producing + KTS
and –KTS isoforms [10]. Both EWS-WT1 -KTS and
EWS-WT1 + KTS have been described in DSRCT, though
is still not clear from which isoform the oncogenic proper-
ties of EWS-WT1 come [11].
Thus, the JN-DSRCT-1 cell line, which presents the
morphologic and genetic characteristics of DSRCT, is an
in vitro preclinical model useful for studies on the
pathogenesis of the disease and for the selection of po-
tential effective drugs.
The aim of our study was the cellular and molecular
characterization of one of the in vitro model of DSRCT,
JN-DSRCT-1, obtained in S.B. Lee’s laboratory, and investi-
gation of the mode of action of trabectedin in this sarcoma.
Methods
Drugs
Trabectedin was provided as a lyophilized formulation by
PharmaMar (S.A. Colmenar Viejo, Spain), dissolved in
DMSO and stored at -20 °C. Just before use, the drug was
diluted in a 1:1 mix of DMEM and Hams F12 medium,
supplemented with 10% Fetal Bovine Serum (FBS) and
2 mM glutamine.
Cell culture
JN-DSRCT-1 cells were grown in a 1:1 mix of DMEM
and Hams F12 supplemented with 10% FBS and 2 mM
glutamine, in a humidified incubator at 37 °C with 5%
CO2. This cell line was a kind gift from S.B. Lee.
RNA extraction, RT-PCR analysis and microarrays
Total RNA was extracted and purified using a commercial
kit (miRNAesy Qiagen, Milan, Italy) from 1 × 106 cells;
this step was partly mechanized, using an automatic ex-
traction system (Qiacube, Qiagen). The amount of total
RNA was determined by UV spectrophotometry using the
NanoDrop Spectrophotometer (Nanodrop Technology,
Wilmington, USA). One μg of total RNA was reverse-
transcribed using the High-Capacity cDNA Archive Kit
following the manufacturer’s instructions (Applied Biosys-
tems, California, USA) to assess the differential expression
of genes in control cells and cells treated with trabectedin
by quantitative real-time PCR (q-PCR). All qPCRs were
done in a 25 μl final volume, with three replicates per
sample, using QuantiFast SYBR Green PCR kit (Qiagen),
and run in an ABI PRISM® 7700 Sequence Detection
System (Applied Biosystems). The data were analyzed
using the default and variable parameters available in the
SDS software package (version 1.9.1; Applied Biosystems).
GAPDH housekeeping control gene was used to
normalize target gene expression levels and the mRNA
amount of each target gene relative to GAPDH was calcu-
lated by the comparative Ct method, also called the
2(−ΔΔCt) method. Two biological replicates were each
assayed in triplicate and results were expressed as mean ±
standard deviation (SD). For microarray experiments,
0.15 μg of RNA were labeled with Cy3 and hybridized ac-
cording to the manufacturer’s instructions (Agilent Tech-
nologies, Palo Alto, CA, USA). After 20 h incubation at 65 °
C in rotation at 20 rpm, arrays were washed and scanned
with a laser confocal scanner (G2565B, Agilent Technolo-
gies, Santa Clara, USA). The microarray underwent standard
post-hybridization processing, and signal intensity was cal-
culated with Agilent Feature Extraction (Agilent Technolo-
gies), version 11.5 (Agilent Technologies).
Raw data from the scanner were then pre-processed,
removing features marked as unreliable by the software,
and arrays were normalized using the “quantile” method
[12], without background correction. Differentially
expressed genes (DEGs) were calculated with linear
models applied to microarray analysis [13], correcting
the test p-value for multiple testing using the False
Discover Rate method [14]. Genes were called significant
if their corrected p-value (q-value) was lower than 0.05,
corresponding to a 5% maximum of false positives.
Functional enrichment analysis used Fisher’s Exact
Test [15] and topological methods [16]. Pathways were
called significant if the test corrected p-value was 0.05 or
lower. Putative network reconstruction based on the sci-
entific literature was done with Ingenuity Pathway Ana-
lysis (IPA; Qiagen, USA). Clustering analysis was carried
out using the Pearson’s correlation coefficient as a meas-
ure of similarity, and with complete linkage.
In accordance to the MIAME guidelines, microarray
data were submitted to Array Express (ID E-MTAB-4532).
Fluorescent in situ hybridization
Fluorescence in situ hybridization (FISH) was used to de-
tect the EWS-WT1 fusion. FISH was done on chromosome
preparations from JN-DSRCT-1 cell line. EWS gene status
was assessed by the Vysis EWSR1 dual color break-apart
probe (Abbott Molecular, Illinois, USA). WT1 gene status
was assessed by the break-apart approach using in-house
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labeled BAC clones (obtained from C.H.O.R.I. Children’s
Hospital Oakland Research Institute): RP1- 259 N9 map-
ping at the WT1 5’ end and RP11-299P16 mapping at the
WT1 3’ end labelled in Spectrum Orange and Spectrum
Green (Abbott Molecular), respectively. Probe labeling was
carried out according to the manufacturer’s instructions.
Slide treatment and FISH experiments were run using
standard procedures [17].
Clonogenic assay, pharmacological treatments and cell
cycle analysis
The JN-DSRCT-1 cells were seeded in six-well plates
(Eppendorf, Hamburg, Germany) at a concentration of 3500
cells/ml. The clonogenic assay was done as previously de-
scribed [18]: cells were treated with different concentrations
of trabectedin for 1 h and the formation of colonies was
evaluated after 5 days. The IC50 for each drug was calculated
with GraphPad PRISM 6.0. The cell cycle perturbations in-
duced by trabectedin were evaluated by standard flow cyto-
metric methods using FACS Calibur. Control and treated
cells were counted using a Coulter Counter (ZM, Beckman
Coulter, Brea, CA, USA) after 1 h of treatment and, 24, 48
and 72 hs after drug washout and fixed in 70% ethanol be-
fore DNA staining. Data was analyzed using Cell Quest.
Sanger sequencing method
Total RNA was extracted with an RNeasy Mini Kit (Qiagen)
from about 2 × 106 JN-DSRCT-1 cells. Total RNA was de-
termined by UV spectrophotometry using the Nano Drop
Spectrophotometer (Nanodrop Technology) and 500 ng of
total RNA were reversed-transcribed using the High-
Capacity cDNA Archive Kit following the manufacturer’s in-
structions (Applied Biosystems). Touchdown PCR reactions
were run in a final volume of 20 μl of 1× PCR Buffer (5×
Colorless Go Taq Flexi Buffer, Promega, Milano, Italy),
200 μM dNTPs mix (Sigma Aldrich, Milano, Italy), 1.5 mM
MgCl2 (Magnesium Chloride Solution, 25 mM, Promega),
0.5 U GoTaq Hot Start Polymerase (Promega), 50 ng of JN-
DSRCT-1 of first strand cDNA, 0.5 μM primer #1 (FW: 5’-
TCCTACAGCCAAGCTCCAAGT-3’, Tm= 59.8 °C; Euro-
fins Genomics Europe, Ebersberg, Germany) and 0.5 μM
primer #3 (RV: 5’-ACTTTTTCTGACAACTTGGC-3’, Tm
= 53.2 °C; Eurofins Genomics Europe) belonging respectively
on the EWS (3’-end of exon 7) and WT1 (5’-end of exon
10) regions of the EWS-WT1 chimera (Additional file 1).
Amplification was done in a C1000 Thermal Cycler (Bio-
Rad, Segrate, Italy) using the following thermal profile: 2‘at
95 °C for 1 cycle, 30” at 95 °C, 30” at 63 °C (with 0.5 °C de-
crease at each cycle) and 40” at 72 °C for 26 cycles, 30” at
95 °C, 30” at 50 °C and 40” at 72 °C for 14 cycles, 5’ at 72 °C
for 1 cycle; the amplicons of expected size ~320 bp and
~530 bp, corresponding to transcript variants A and B re-
spectively, were separated by 2% 1× TAE buffer agarose gel
electrophoresis. To have a pure solution of each transcript
variant for the Sanger sequencing, a small amount of each
band was picked up from gel with a p200 pipette-tip, eluted
for at least 3 h in 20 μl of PCR-grade ddH2O and subjected,
individually, to Touchdown PCR amplification as described
above (using 1 μl of each eluted product as template). The
quality and the amount of the pure ~320 bp and ~530 bp
amplicons was verified by 2% 1× TAE buffer agarose gel
electrophoresis loading a small volume (about 3 μl) of each
Touchdown PCR. The remainder of each PCR amplification
was purified using the QIAquick PCR purification Kit
(Qiagen). Both strands of the two purified variants were
Sanger sequenced in a 3130-16 Genetic Analyzer using the
appropriate primer (Additional file 1 Primer #4, FW: 5’-
AGAAACCATACCAGTGTGAC-3’, Tm= 55.3 °C; Eurofins
Genomics Europe Primer#2, REV: 5’-ACCTTCGGTTCA-
CAGTCCTTG-3’, Tm= 59.8 °C; Eurofins Genomics
Europe) and the BigDye Direct Cycle Sequencing Kit,
according to the manufacturer’s instructions (Thermo-
Fisher Scientific, Monza, Italy).
Animals and in vivo experiments
To obtain the desmoplastic xenografts, 200 μl of cell sus-
pension containing 5 × 107 cells were injected s.c. into the
flanks of NOD- SCID GAMMA (NSG) mice. Desmoplas-
tic xenografts were then obtained by transplanting 2–
3 mm tumor fragments s.c. in the flanks of nude mice.
Chromatin immunoprecipitation analysis (ChIP)
Cells and tumors were crosslinked with 1% formaldehyde.
After quenching with glycine, chromatin was sheared by
sonication (Bioruptor Diagenode, Seraing, Belgium) in frag-
ments around 500–800 bp. Chromatin immunoprecipita-
tions were done using mouse monoclonal EWS G-5
(sc28327), rabbit polyclonal WT1 C-19 (sc192) and rabbit
IgG (7074S, Cell Signaling, Danvers, USA) as negative
control. The ChIPped DNA was then re-suspended in
water and analyzed by RT-PCR. The detailed procedure of
Chromatin Immunoprecipitation analysis was described by
Di Giandomenico et al [8]. Data were analyzed according
to the fold enrichment method. The sequences of the
primers are listed in Additional file 2.
Western blot analysis
JN-DSRCT-1 cells were treated with 5nM trabectedin for
1 h. After 48 and 72 h drug washout, total extracts were pre-
pared from 2 × 106 cells collected in Ripa Buffer (50 mM
TRIS-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA 500 mM,
1% Triton, 1 mM DTT, 1 mM PMSF, 1× PIC); after centri-
fuged 10 min at 13,000 rpm 4 °C, the supernatants were
stocked at -80 °C. 20 μg of total extracts were used in a
SDS-PAGE. Proteinswere transferred to nitrocellulose and
analyzed by western blotting with mouse monoclonal EWS
G-5 (sc28327), rabbit polyclonal WT1 C-19 (sc192) and goat
polyclonal ACTIN (C-11) (sc1615).
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Statistical analysis
We used GraphPad PRISM 6 software for statistical ana-
lysis. For RT-Q-PCR data we used the unpaired t test and
changes were considered significant at a p value <0.005.
For ChIP RT-Q-PCR we used the paired t test and
changes were considered significant at a p value <0.005.
Results
The JN-DSRCT-1 cell line recapitulates DSRCT disease
characteristics
We characterized the JN-DSRCT-1 cell line, which derived
from a patient with DSRCT [9]. This cell line grows well in
vitro with a doubling time of 36 h. Its morphology was con-
firmed: the shape of the cells was similar to that in biopsies
from patients (Fig. 1a). Moreover, JN-DSRCT-1 cells express
the EWS-WT1 chimera, as demonstrated by FISH analysis
in Fig. 1b, where nuclei in interphase of JN-DSRCT-1 cells
clearly reveal the t(11;22)(p13;q12) translocation, leading to
the fusion protein EWS-WT1.
JN-DSRCT-1 cells are sensitive to trabectedin
We further characterized the DSRCT cell line, testing its
sensitivity to trabectedin. The clonogenic assay showed that
JN-DSRCT-1 cells are very sensitive to trabectedin, with an
IC50 around 4.5 nM (Fig. 1c). Cell cycle analysis indicated
that 2.5 nM (the IC20 at 24 h after drug washout) of trabec-
tedin for 1 h induced a G2/M block already evident at 24 h
after drug wash-out. This block was overcome 72 h after
drug wash-out. Higher doses of trabectedin, 5 and 10 nM,
that represent the IC40 and IC50, respectively, induced cell
cycle perturbations that were still partially present 72 h
after drug wash-out (Fig. 1d). We do not have any evi-
dences of apoptotic activation, as assessed by biochemical
assay (i.e. caspase activity assay, data not shown).
JN-DSRCT-1 cells present heterogeneity of EWS-WT1
transcripts
We checked the mRNA level of EWS-WT1 transcripts by
Q-RT-PCR and protein levels by Western Blot. We designed
ad hoc primers amplifying EWS-WT1 transcripts, using a
forward primer annealing on exon 7 of EWS and a reverse
primer annealing on exon 8 of WT1, so we could distin-
guish the single endogenous proteins from the chimeric
ones. We ran RT-Q-PCR on mRNA extracted from JN-
DSRCT-1 cells, before trabectedin treatment and after 1 h
of 5 nM treatment and 24 h of drug wash out, and verified
Fig. 2 EWS-WT1 transcript heterogeneity in JN-DSRCT-1 cell line. a mRNA levels of EWS-WT1 chimera before and after 1 h of trabectedin 5 nM and
24 h after drug wash-out. Data are shown according to the Fold change method using PRISM GraphPad software.* p value < 0.005. b EWS-WT1 protein
levels detected with antibodies against EWS (G-5, sc28327), WT1 (C-19, sc192), ACTIN (C-11, sc-1615). Western blot analysis of total extracts deriving
from: lane 1, JN-DSRCT-1 cells untreated; lane 2, JN-DSRCT-1 cells 1hT48hR (1 h 5nM trabectedin treatment and 48 h after drug wash-out); lane 3,
JN-DSRCT-1 cells 1hT72hR (1 h 5nM trabectedin treatment and 72 h after drug wash-out); lane 4, OVCAR5 cells. c EWS-WT1 chimeric structure diagram
and different isoforms of EWS-WT1 chimera, in JN-DSRCT-1 cells. d EWS-WT1 variant transcripts with or without KTS domain in JN-DSRCT-1 cells
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the expression of EWS-WT1 transcript and protein (Fig. 2a-
b): mRNA level of the EWS-WT1 chimera was downregu-
lated, but not the protein levels. Next, to characterize the
chimera transcript better, we did a DNA Sanger sequencing.
The simultaneous presence of two major transcripts
emerged, the first characterized by the fusion of exons 1–7
and 10 of EWS gene to exons 8–10 of WT1, marked in
Fig. 2b as (a), and the second by the fusion of exons 1–10 of
EWS gene to exons 8–10 of WT1 gene, marked in Fig. 2b
as (b). Analysis of transcript b showed that almost 50% of
this variant contained a small deletion (3 bp: AGC = > Ser)
in the 5’ end of Exon 9 of EWS gene, marked as (c). All
these variants were present in two sub types, with or with-
out the KTS (Lys-Thr-Ser) domain, located between the zinc
finger 3 and 4 of exon 9 of WT1 gene (Fig. 2c). Liu et al. also
reported these different isoforms in a study of 14 DSRCT
tumors [19]. Thus, the JN-DSRCT-1 cell line showed broad
heterogeneity in EWS-WT1 transcripts.
Trabectedin’s effects on EWS-WT1 expression and function
We examined whether trabectedin reduced the EWS-WT1
chimera binding on its target promoters, through Chroma-
tin Immunoprecipitation (ChIP) assays. We treated cells
with 5 nM trabectedin for 1 h, and with 0.5 and 0.75 nM
for 24 h. We analyzed three different promoters belonging
to EWS-WT1 published target genes, IGF2, PDGFA and
EGFR [10]. Trabectedin significantly reduced EWS-WT1
binding, particularly on the EGFR promoter after 1 h with
5 nM trabectedin and 24 h with 0.5 nM trabectedin
(Fig. 3a). Then we investigated the kinetics of reattachment
of the chimera, on cells recovered 6 and 24 h after treat-
ment: trabectedin kept the reduced binding of the chimeric
protein on the EGFR promoter but not on ENT-4 pro-
moter, another target gene bound by EWS-WT1 chimera
[3], where the aberrant trascription factor binding was re-
stored already 6 h after drug wash-out (Fig. 3b).
Expression profiling of JN-DSRCT-1 cells treated with
trabectedin suggests an arrest in tumor progression
To determine whether trabectedin altered the expression of
EWS-WT1 target genes, we did a whole-transcriptome
expression profiling of JN-DSRCT-1, treated with 5 nM
trabectedin 6, 12 and 24 h after drug wash-out. One of the
control samples failed the quality checks and was discarded.
Unsupervised clustering analysis (Additional file 3)
showed an almost unambiguous separation of the control
samples from those treated with trabectedin, indicating
that the changes in gene expression elicited by the drug
were sufficiently higher than the signal background to
warrant further analyses.
Fig. 3 Trabectedin displaces EWS-WT1 chimera from its target gene promoters. a ChIP assays on JN-DSRCT-1, treated and not with trabectedin 5 nM
for 1 h, 0.5 nM and 0.75 nM for 24 h. The binding of EWS-WT1 on IGF2, PDGFA and EGFR was analyzed by RT-Q-PCR. Data are shown according to the
Fold enrichment method using PRISM GraphPad software. * p value < 0.005. b ChIP assays on JN-DSRCT-1, treated and not with trabectedin 5 nM for
1 h, and recovered after 6 and 24 h. The binding of EWS-WT1 on EGFR and ENT-4 was analyzed by RT-Q-PCR. Data are shown according to the Fold
enrichment method using PRISM GraphPad software. * p value < 0.005
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Differentially expressed genes (DEGs) were then calcu-
lated by comparing each time against the untreated con-
trol (Additional file 4).
We then analyzed differentially expressed genes
(DEGs) 6, 12, and 24 h after drug wash-out. The number
of DEGs was higher at 6 h (1417 unique DEGs) when
compared to 12 and 24 h (244 and 26, respectively), sug-
gesting the presence of off-target effects at later time
points. Thus, to better identify on-target drug effects, we
focused on the analysis at 6 h after drug wash out. This
analysis identified 1417 unique DEGs (619 up-regulated,
798 down-regulated), including up-regulation of several
caspase genes (CASP3, CASP8, CASP10) and down-
regulation of PDGFa (Additional file 4). Functional
analysis on the DEGs identified the activation of
apoptosis-related pathways (p53 signaling and effectors,
caspase cascades), activation of cytokine-related path-
ways (cytokine-cytokine receptor interaction, TNF
signaling) and the inhibition of Rap and Ras-related
pathways (Additional file 5).
To gain additional information on the processes involved,
we reconstructed networks based on interactions taken
from the current literature using IPA (Fig. 4). Down-
regulation of TNF, AR, VEGFA and the up-regulation of
GDF15 and SAT1 were part of a predicted network involv-
ing SMAD4, MDM2 and TP53, known to be involved in
the inhibition of tumor proliferation and progression.
These results suggest that the bulk of the expression
changes led by trabectedin on JN-DSRCT1 occur in the
early time points, and that the treatment induces
mechanisms related to apoptosis (p53 signaling, caspase
cascades) and inhibition of proliferation.
In vivo experiments
We could not obtain growth of JN-DSRCT-1 inoculated in
nude mice, so we transplanted desmoplastic sarcoma cells in
more immunodeficient nude SCID mice, observing a tumor
take in a small percentage; sections of tumors, from these
DSRCT xenograft models, had monomorphic short spindle
cells arranged in solid nests with scanty desmoplastic inter-
posed stroma (Fig. 5). The lack of reproducible tumor growth
made it difficult to further investigate the activity and the
mode of action of trabectedin in these xenografts.
Discussion
The EWS-WT1 is considered the pathogenic lesion of
DSRCT. It is composed of the N-terminal domain of the
Fig. 4 Network analysis of differentially expressed genes (DEGs) after 6 h of trabectedin treatment versus untreated control indicates an inhibition
of tumor progression. Solid arrows indicate direct interaction, dashed lines indirect interaction. Green, down-regulated gene in the data set; red,
up-regulated gene in the data set; orange, predicted activation inferred from the state of the present genes; blue, predicted inhibition inferred
from the state of the present genes. Blue lines between genes indicate that the process leads to inhibition, while orange lines indicate activation.
Grey lines indicate absence of any significant predicted effect
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EWS gene and of the C-terminal DNA binding domain of
the WT1 tumor suppressor gene [11]. EWS encodes a pu-
tative RNA binding protein of unknown function, whose
N-terminal domain mediates potent transcriptional activa-
tion when fused to heterologous DNA binding domains.
The fusion protein activates a limited number of target
genes that are sufficient to trigger malignant proliferation.
Since the EWS-WT1 chimera does not contain the first of
the four zinc fingers of WT1, it has been reported that an
altered DNA binding domain may be essential for cellular
transformation in DSRCT. Moreover, the distinct transac-
tivation domain conferred by the N-terminal domain of
EWS is likely to lead to interactions with other compo-
nents of the transcriptional machinery, which may be re-
cruited to target promoters, thus contributing to different
targets for these related transcription factors.
We have confirmed that JN-DSRCT-1 cells, which are one
of the in vitro model of DSRCT, harbor the t(11;22)(p13;q12)
translocation, which underlies this tumor and genetic events
triggering malignant transformation. Next, we investigated all
the EWS-WT1 isoforms expressed in the DSRCT cell line
model, and found six different transcripts. Thus, JN-DSRCT-
1 cells display a broadly heterogeneous transcript population.
Then, having demonstrated that JN-DSRCT-1 cells are par-
ticularly sensitive to trabectedin, with a strong G2/M block,
we investigated whether the drug affected the binding of
EWS-WT1 chimera to DNA sequence within target pro-
moters, like the FUS-CHOP chimera in MLS disease or the
EWS-FLI1 in Ewing Sarcoma [8, 20]. We found that EWS-
WT1 transcript levels are affected by trabectedin treatment,
to a slight but significative degree, and that the drug causes a
quantitative decrease in the binding of the aberrant
trascription factor to its target promoters. Therefore the de-
crease of chimera binding might be due at least in part to the
decrease in EWS-WT1 transcripts produced in the cell after
drug treatment, not only to a direct effect of trabectedin on
the binding. However, expression profiling results suggested
that trabectedin has significant effects on the transcriptional
programs of JN-DSRCT-1 cells: in particular genes involved
in apoptosis are induced and genes involved in proliferation
are inhibited at early time points after drug treatment.
Conclusions
JN-DSRCT-1 cells expressing the chimeric fusion products
are sensitive to trabectedin; they show significant reduction
of mRNA levels of the chimeric protein and decreased
binding of EWS-WT1 chimera on its target promoters.
The heterogeneity of EWS-WT1 transcripts represents an
obstacle to the precise definition of the mode of action of
trabectedin or other potential drugs, indicating the need of
other cellular models for this disease. In this respect,
recently other cell lines derived from DSRCT have been
reported [21]; these cells could be used to verify the activity
and the mechanism of action of trabectedin.
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